ReviewCurrent atherosclerosis reports2025
Circular RNA role in Atherosclerosis Development and Progression.
Review in Current atherosclerosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Kidney-heart crosstalk: the extracellular vesicles connection.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Single-cell Technologies in Atherosclerosis: Uncovering Cellular Heterogeneity, Mechanisms, and Therapeutic Opportunities.Current atherosclerosis reports · 2026Review
- Diagnostic potential of circular RNAs in carotid atherosclerotic plaque vulnerability.Non-coding RNA research · 2026Article
- CircATXN2 exacerbates pulmonary arterial hypertension by modulating the miR-138-5p/SMURF1 axis.Respiratory research · 2026Article
- RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside.Research (Washington, D.C.) · 2026Article
- Differential Expression of Circular RNAs in Rat Brain Regions with Various Degrees of Damage After Ischemia-Reperfusion.International journal of molecular sciences · 2025Article
- Circular RNAs in Cardiovascular Disease: Mechanisms, Biomarkers, and Therapeutic Frontiers.Biomolecules · 2025Review
- Mechanisms of circular RNAs in diabetic cardiomyopathy: biological characteristics and clinical prospects.Frontiers in genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewCircular RNAs (circRNAs), a distinct class of long noncoding RNAs characterized by covalently closed-loop structures, have emerged as pivotal regulators of gene expression. Their stability, abundance, and cell-type specificity make them increasingly relevant in cardiovascular disease pathogenesis and clinical management. Atherosclerosis, a chronic inflammatory disorder of the arterial wall, underlies many cardiovascular and cerebrovascular events, including myocardial infarction and stroke. This review provides a comprehensive analysis of circRNAs' influence on the development and progression of atherosclerotic plaques. RECENT
findingsThe role of circRNAs in atherogenesis, where they may function as atheroprotective or atherogenic factors by modulating endothelial and smooth muscle cell functions, macrophage activity, lipid metabolism, and inflammatory signaling, has recently emerged. This review explores both experimental and in vivo findings on the functions of specific circRNAs and their involvement in cellular autophagy, apoptosis, oxidative stress, and vascular remodeling. Additionally, the diagnostic potential of circulating circRNAs as biomarkers for plaque instability and rupture has been investigated. Understanding circRNA-mediated regulatory networks may open new avenues for precision diagnostics and targeted therapies in atherosclerotic cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.